Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | PHASE2 | ACTIVE NOT_RECRUITING | 231 | — | — | Oct 8, 2019 | Sep 1, 2025 | Jan 27, 2025 | 56 | United States, Australia +8 |
| Arm | Type | Description |
|---|---|---|
| Cemiplimab in combination with RP1 | EXPERIMENTAL | Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks |
| Cemiplimab | ACTIVE_COMPARATOR | Cemiplimab administered intravenously as a single therapy every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Cemiplimab | DRUG | Cemiplimab administered intravenously |
| RP1 | BIOLOGICAL | RP1 administered intratumorally |
Key Inclusion Criteria: * Histologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma * Patients with locally advanced disease who are not suitable candidates for surgical or radiological treatment of lesions or have refused those treatments * At least 1 lesion that is...